238 related articles for article (PubMed ID: 35870026)
1. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature.
Virgilio E; Tondo G; Montabone C; Comi C
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612789
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature.
Ramdas S; Hum RM; Price A; Paul A; Bland J; Burke G; Farrugia M; Palace J; Storrie A; Ho P; Standing E; Lilleker JB; Jungbluth H
Neuromuscul Disord; 2022 Oct; 32(10):785-789. PubMed ID: 36130855
[TBL] [Abstract][Full Text] [Related]
4. New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 Vaccine.
Slavin E; Fitzig J; Neubert C; Garcia-Lopez F; Cuevas-Trisan R
Am J Phys Med Rehabil; 2022 Dec; 101(12):e176-e179. PubMed ID: 35930797
[TBL] [Abstract][Full Text] [Related]
5. Temporal association between SARS-CoV-2 and new-onset myasthenia gravis: is it causal or coincidental?
Muralidhar Reddy Y; B SK; Osman S; Murthy JMK
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290032
[TBL] [Abstract][Full Text] [Related]
6. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
Gamez J; Gamez A; Carmona F
Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
[TBL] [Abstract][Full Text] [Related]
7. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
Sansone G; Bonifati DM
J Neurol; 2022 Aug; 269(8):3965-3981. PubMed ID: 35503373
[TBL] [Abstract][Full Text] [Related]
8. Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.
Zheng W; Cao X; Luo J; Liu Z; Que W; Guo X; Fan R; Long Q; Xiao F
Neurol Sci; 2024 Apr; 45(4):1707-1717. PubMed ID: 37940750
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.
Peric S; Rankovic M; Bozovic I; Radosavljevic V; Marjanovic I; Basta I; Lavrnic D
Acta Neurol Belg; 2023 Apr; 123(2):529-536. PubMed ID: 36279094
[TBL] [Abstract][Full Text] [Related]
11. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
Doron A; Piura Y; Vigiser I; Kolb H; Regev K; Nesher N; Karni A
J Neurol; 2022 Dec; 269(12):6193-6201. PubMed ID: 35907046
[TBL] [Abstract][Full Text] [Related]
12. Spontaneously resolving late-onset ocular myasthenia related to COVID-19. A case report.
Popescu C
Acta Myol; 2023; 42(2-3):89-91. PubMed ID: 38090545
[TBL] [Abstract][Full Text] [Related]
13. A Case of COVID-19 Vaccine Associated New Diagnosis Myasthenia Gravis.
Chavez A; Pougnier C
J Prim Care Community Health; 2021; 12():21501327211051933. PubMed ID: 34709075
[TBL] [Abstract][Full Text] [Related]
14. New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
Tereshko Y; Gigli GL; Pez S; De Pellegrin A; Valente M
J Neurol; 2023 Feb; 270(2):601-609. PubMed ID: 36352330
[TBL] [Abstract][Full Text] [Related]
15. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
[TBL] [Abstract][Full Text] [Related]
16. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection.
Assini A; Gandoglia I; Damato V; Rikani K; Evoli A; Del Sette M
Eur J Neurol; 2021 Oct; 28(10):3537-3539. PubMed ID: 33421278
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine.
Hoshina Y; Sowers C; Baker V
Eur J Case Rep Intern Med; 2022; 9(7):003439. PubMed ID: 36051160
[TBL] [Abstract][Full Text] [Related]
18. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
[TBL] [Abstract][Full Text] [Related]
19. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.
Li HY; Shao LY; Song M; Hu SM; Yue YX; Li HF
Front Immunol; 2022; 13():923017. PubMed ID: 35990671
[TBL] [Abstract][Full Text] [Related]
20. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.
Zhou Q; Zhou R; Yang H; Yang H
Front Immunol; 2021; 12():733418. PubMed ID: 34603311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
